Agenus (AGEN) vs Larimar Therapeutics (LRMR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Agenus (AGEN) has outperformed Larimar Therapeutics (LRMR) over the past year, gaining 80.8% versus a loss of 44.0%. Over five years, LRMR leads with a -77.7% price change compared with -92.8% for AGEN. Agenus is the larger company by market cap ($341.2 million vs $282.0 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGEN | LRMR |
|---|---|---|
| Share price | $7.56 | $2.72 |
| Market cap | $341.20M | $282.04M |
| 1-day change | +0.20% | +0.56% |
| YTD return | +140.13% | -29.13% |
| 1-year return | +80.82% | -43.98% |
| 5-year return | -92.77% | -77.72% |
| P/E ratio (TTM) | 2.99 | — |
| EPS (TTM) | $2.53 | $-1.99 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.31 | $6.42 |
| 52-week low | $2.71 | $2.61 |
| Distance from 52-week high | -26.72% | -57.71% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +248.51% | +430.39% |
| Average volume | 4.26M | 1.27M |
| Shares outstanding | 45.16M | 103.88M |
| Employees | 81 | 71 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AGEN has outperformed LRMR by 124.8 percentage points over the past year.
About Agenus
AGEN stock →Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 81 employees
About Larimar Therapeutics
LRMR stock →Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 71 employees
AGEN vs LRMR FAQ
Which is bigger, Agenus or Larimar Therapeutics?
Agenus (AGEN) is larger, with a market capitalization of $341.20M compared with $282.04M for Larimar Therapeutics (LRMR).
Which stock has performed better over the past year, AGEN or LRMR?
AGEN returned +80.82% over the past 12 months, compared with -43.98% for LRMR (price return, excluding dividends). Past performance does not predict future results.
Are Agenus and Larimar Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Agenus and Biotechnology: Pharmaceutical Preparations for Larimar Therapeutics.